You are here

Article Text

Article menu
Download PDFPDF
Editorial
The emergence of a new specialty of oncocardiology
  1. Parva K Bhatt,
  2. Tochi Okwuosa
  1. Rush University Medical Center, Chicago, Illinois, USA
  1. Correspondence to Dr Tochi Okwuosa, Rush University Medical Center, Chicago, IL 60612-3833, USA; tokwuosa{at}rush.edu

http://dx.doi.org/10.1136/postgradmedj-2016-134440

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Advances in the field of oncology research and therapy have led to improved outcomes and survival in patients with cancer. Projections from the SEER (Surveillance, Epidemiology, and End Results) database have shown a decreasing cancer incidence, with increasing survival now and in the coming years.1 With increasing survivorship, the prevalence of cardiotoxicities has also increased.2 Therefore, primary and oncology providers are encountering uncharted territory in the management of cancer therapy-related toxicities in their oncology patients and survivors.2 It is the need to manage these complications that has led to the development and growth of the field of oncocardiology.2 ,3 This editorial seeks to briefly summarise important aspects of oncocardiology and emphasise the necessity in growing this field.

    The field of oncocardiology predominantly focuses on cardiotoxic effects of cancer therapy (chemotherapy, radiation therapy and/or targeted therapy). Cardiotoxicity related to cancer therapy not only involves the development of cardiomyopathy by way of reduction in left ventricular ejection fraction (LVEF) …

    View Full Text

    Footnotes

    • Contributors PKB was responsible for the initial writing of the manuscript. TO reviewed and edited the manuscript for syntax, grammar and content.

    • Competing interests None.

    • Provenance and peer review Not commissioned; internally peer reviewed.